Article Text

Download PDFPDF

A9.14 Regulatory T Cell Abnormalities in Patients with SLE Suggest an IL-2-Based Immunotherapy
  1. C von Spee1,2,
  2. N Wassermann2,
  3. JY Humrich1,2,*,
  4. G Riemekasten1,2,*
  1. 1German Rheumatism Research Centre, Berlin, Germany
  2. 2Charité University Hospital, Rheumatology and Clinical Immunology, Berlin, Germany.


Background Phenotypic and quantitative abnormalities of regulatory T cells have been described in association with systemic lupus erythematosus (SLE). Further, an impaired production of IL-2, the essential cytokine for Treg homeostasis, has been described for T cells from SLE patients. Here, we aim to substantiate the link between IL-2 deficiency and Treg abnormalities in SLE and to provide the basis for an IL-2 based immunotherapy.

Methods Phenotype, frequency and homeostatic status of Foxp3+CD127lo Treg and conventional Foxp3- T cell (Tcon) subsets were analysed by multi-colour flow-cytometry of PBMCs from SLE patients and healthy donors ex vivo and after in vitro low-dose IL-2 treatment. Disease activity was determined according to the SLE activity index (SLEDAI). Two-tailed Mann-Whitney U test or 2-way ANOVA test were used for statistical analysis between patient or treatment groups, Spearman’s rank coefficient was used to calculate correlations with disease activity.

Results The frequency of CD25+ cells among Treg was significantly reduced in SLE patients compared to HC. Analysis of Ki67 expression revealed that proliferation was significantly increased in Tcon from SLE patients, resulting in a reduced Treg to Tcon proliferation ratio in SLE patients. The proliferation ratio correlated positively with the frequency of CD25+ Treg and inversely with disease activity. Treatment of SLE PBMCs with low-dose IL-2 in vitro resulted in increased frequencies of CD25+ cells among Treg and increased CD25 expression levels on Treg. Treg, but not Tcon proliferation was significantly increased under low-dose IL-2 treatment compared to untreated controls.

Discussion Similar to what has been observed in lupus-prone mice and IL-2-/- mice, Treg from SLE patients show the classical hallmarks of IL-2 deficiency with loss of CD25 expression and impaired homeostasis. Our in vitro results show that these Treg defects can be restored by low-dose IL-2 treatment, suggesting IL-2 as a novel therapeutic target for SLE.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.